Compare CRMT & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | CNSY |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 20.6M |
| IPO Year | 2026 | 2016 |
| Metric | CRMT | CNSY |
|---|---|---|
| Price | $2.35 | $2.69 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $29.50 | N/A |
| AVG Volume (30 Days) | ★ 176.9K | 64.0K |
| Earning Date | 06-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.38 | $2.62 |
| 52 Week High | $37.45 | $4.03 |
| Indicator | CRMT | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 27.14 |
| Support Level | $2.13 | $2.62 |
| Resistance Level | $3.67 | $3.05 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 24.19 | 10.73 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.